Lilly sets the bar for amylin with eloralintide weight loss data

Just as it did with GLP-1 agonists, Lilly is again setting the benchmark by which all other molecules will be measured — only this time with an amylin monotherapy. Phase II data from the pharma’s eloralintide showed weight loss on par with its blockbuster Zepbound tirzepatide, but with an improved tolerability profile that raises the prospect of amylin becoming standard-of-care therapy for obesity. 

While not deal-breakers, the findings cast further doubt on amylin’s muscle-sparing ability and showed that fatigue occurred more often with eloralintide than with GLP-1s...